Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice
Open Access
- 1 May 1993
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 67 (5) , 939-944
- https://doi.org/10.1038/bjc.1993.174
Abstract
HuIL-6 cDNA, cloned into a neomycin resistant conferring expression vector, BMGNeo, was transfected into Lewis Lung Carcinoma (LLC) cells. LLC cells (5 x 10(6) ml-1) transfected with IL-6 cDNA (LLC-IL6) secreted IL-6 into the culture supernatant at a concentration of 9.9 ng ml-1 within 48 h. When 1,000,000 of untransfected LLC, BMGNeo vector transfected LLC (LLC-Neo) or LLC-IL6 cells were transplanted into C57BL/6 mice subcutaneously, the mean +/- s.d. of survival times of these mice were 33.3 +/- 9.7, 34.3 +/- 7.1 and 17.0 +/- 3.1 days, respectively. The survival time of LLC-IL6 cells transplanted mice was significantly shorter than that of LLC (P < 0.01) or LLC-Neo (P < 0.01) cells transplanted mice without a measurable difference of tumour size. Plasma concentration of IL-6 steadily increased in LLC-IL6 transplanted mice. Body weight and serum albumin were significantly lower in LLC-IL6 transplanted mice than in LLC transplanted mice. Mouse IL-1 alpha and mouse TNF-alpha were not detected in the plasma of LLC-IL6 transplanted mice. These data suggested that secretion of IL-6 from LLC cells was unable to alter net tumour growth rate but rather caused a state similar to cachexia without detectable increase of IL-1 alpha and TNF-alpha in the plasma. This state may be responsible for the shortened survival of LLC-IL6 tumour-bearing mice.Keywords
This publication has 24 references indexed in Scilit:
- Tumor necrosis factor‐α and interleukin‐1α production in cachectic, tumor‐bearing miceInternational Journal of Cancer, 1990
- Interleukin-6: An OverviewAnnual Review of Immunology, 1990
- Stimulation of thrombopoiesis in mice by human recombinant interleukin 6.Journal of Clinical Investigation, 1990
- Antitumor activity of recombinant interleukin 6 in mice.The Journal of Experimental Medicine, 1990
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectorsEuropean Journal of Immunology, 1988
- Recombinant human B cell stimulatory factor 2 (BSF‐2/IFN‐β2) regulates β‐fibrinogen and albumin mRNA levels in Fao‐9 cellsFEBS Letters, 1987
- Tumors secreting human TNF/cachectin induce cachexia in miceCell, 1987
- Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulinNature, 1986
- Antibodies to major histocompatibility antigens produced by hybrid cell linesNature, 1977